NANOCURE

98 % of the human population is chronically infected by EBV. We propose an innovative platform for engineering immunogenic bi-modular fusion proteins comprising a binding moiety and an EBV antigen to redirect an EBV pre-existing immune response towards a select cellular target. The aim is to develop efficient therapies triggering immune mechanisms such as Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) and Antibody- Dependent Phagocytosis (ADP) to combat pathogens or treat pathologies such as cancer.

Applications

• Treatment of cancers (such as B-cell lymphomas)
• Treatment of infectious diseases (such as malaria)

Competitive advantages

• Applicable for 98 % of the population.
• Easy to produce as compared to current therapies such as monoclonal antibodies.
• Triggering of multiple immune effectors due to the recruitment of polyclonal antibodies.
• Allow efficacy improvement of current therapeutic antibodies.
• Versatile platform allowing large scale screening of binding moieties.
• Multiple applications (treatment of a large panel of diseases).

Intellectual property

Patent application filed on June 2017

Keywords

Epstein-Barr Virus - Therapeutic molecular engineering - Antibody fragments - Nanobodies - Immune effectors - Cellular cytotoxicity / complement activation